Table 3.

Vaginal concentrations of steroid pathway metabolites.

		All subjects			Subgroup analysis
		PVD (n = 54)/HC(n = 49)			No hormone subgroup: PVD(n = 25)/HC(n = 29)			Systemic hormone subgroupPVD (N = 22)/HC(n = 14)			PVD Systemic/PVD No hormone			HCSystemic/HC No hormone
Subpathways	Biochemical	Fold Change	P	q	Fold Change	p-value	q-value	Fold Change	p-value	q-value	Fold Change	p-value	q-value	Fold Change	p-value	q-value
Pregnenolone steroids	17alpha-hydroxypregnanolone glucuronide	0.38	0.093	0.125	0.55	0.049	0.117	1.20	0.63	0.74	0.71	0.28	0.82	0.33	0.002	0.129
	21-hydroxypregnenolone disulfate	0.27	0.011	0.039	0.41	0.008	0.061	0.87	0.73	0.79	1.16	0.68	0.96	0.55	0.124	0.422
	pregnenediol disulfate (C21H34O8S2)*	0.20	0.002	0.020	0.22	0.001	0.035	0.65	0.43	0.63	1.37	0.50	0.92	0.47	0.149	0.454
Progestin steroids	5alpha-pregnan-3beta,20beta-diol monosulfate (1)	0.50	0.001	0.016	0.50	0.011	0.063	0.63	0.17	0.48	1.11	0.71	0.97	0.88	0.679	0.845
	5alpha-pregnan-3beta,20alpha-diol disulfate	0.16	0.032	0.069	0.53	0.007	0.057	0.97	0.90	0.85	0.98	0.93	0.99	0.54	0.026	0.254
	pregnanediol-3-glucuronide	0.18	0.009	0.036	0.26	0.003	0.045	1.01	0.99	0.86	0.89	0.80	0.98	0.23	0.007	0.173
Cortico-steroids	Cortisone	1.09	0.135	0.154	1.06	0.663	0.483	1.21	0.29	0.56	0.82	0.19	0.73	0.72	0.057	0.314
Androgenicsteroids	11-ketoetiocholanolone glucuronide	0.52	0.232	0.214	0.68	0.243	0.265	1.14	0.75	0.79	0.86	0.68	0.96	0.52	0.093	0.375
	dehydroisoandrosterone sulfate (DHEA-S)	0.35	0.053	0.090	0.42	0.020	0.080	1.01	0.98	0.86	1.40	0.38	0.90	0.59	0.221	0.525
	16a-hydroxy DHEA 3-sulfate	0.22	0.006	0.029	0.30	0.003	0.045	0.83	0.71	0.78	0.83	0.66	0.96	0.30	0.012	0.216
	androsterone glucuronide	0.63	0.551	0.358	0.64	0.241	0.264	1.50	0.39	0.61	0.83	0.63	0.95	0.36	0.022	0.246
	epiandrosterone sulfate	0.66	0.581	0.373	0.68	0.249	0.267	1.35	0.47	0.65	1.08	0.83	0.98	0.55	0.126	0.423
	androsterone sulfate	0.46	0.337	0.267	0.48	0.089	0.152	1.36	0.57	0.70	1.05	0.91	0.99	0.37	0.055	0.314
	etiocholanolone sulfate	0.68	0.517	0.343	0.56	0.172	0.218	1.16	0.77	0.80	1.22	0.67	0.96	0.59	0.287	0.592
	etiocholanolone glucuronide	0.65	0.692	0.409	0.69	0.361	0.333	1.42	0.48	0.65	0.75	0.51	0.93	0.37	0.038	0.283
	androstenediol (3beta,17beta) monosulfate (1)	0.23	0.143	0.160	0.70	0.051	0.118	0.98	0.92	0.85	1.18	0.39	0.90	0.85	0.443	0.706
	androstenediol (3beta,17beta) disulfate (1)	0.41	0.020	0.051	0.28	0.005	0.049	0.84	0.76	0.79	1.75	0.25	0.80	0.57	0.297	0.599
	androstenediol (3beta,17beta) disulfate (2)	0.31	0.014	0.043	0.28	0.006	0.054	0.84	0.76	0.79	1.31	0.59	0.94	0.43	0.127	0.424
	5alpha-androstan-3alpha,17beta-diol monosulfate (1)	0.99	0.829	0.455	1.00	1.000	0.600	1.00	0.96	0.86	1.09	0.16	0.72	1.10	0.187	0.488
	5alpha-androstan-3beta,17beta-diol disulfate	0.78	0.131	0.151	0.76	0.048	0.116	0.99	0.96	0.86	1.12	0.43	0.90	0.86	0.367	0.655
	andro steroid monosulfate C19H28O6S (1)*	0.32	0.004	0.028	0.33	0.001	0.036	0.89	0.79	0.80	1.03	0.93	0.99	0.38	0.017	0.242

The table shows the main analysis results from comparing provoked vestibulodynia (PVD) and healthy controls (HC) subjects in all subjects (Fold Change, p, q) as well as the false discovery rate corrected p values (q) associated with the hormone subgroup sensitivity analyses. Abbreviations: Fold Change: ratio of means, p =probability, q = 5% false discovery rate corrected p value.